Unconjugated bilirubin disrupts *Plasmodium falciparum* through dual targeting of mitochondrial pyrimidine synthesis and hemozoin formation. Pharmacological inhibition of UGT1A1-mediated bilirubin conjugation creates therapeutic opportunities by exploiting host metabolic defenses as antimalarial weapons, potentially transforming jaundice from pathological symptom into engineered therapeutic advantage.